peplexicon
Choose your depth

Context, anatomy, and key evidence

← Peptide library

vasopressin analog

Terlipressin

Published evidence · coverage incomplete
Anatomical contextAnatomy connections are not mapped yet.

No body region is highlighted until this profile has a supported anatomical connection. This does not mean the peptide has no biological effects.

Read published mechanism findings ↓

At a glance

What is it—and why does it matter?

Terlipressin is described chemically as a peptide composed of 12 amino acids. The product’s active ingredient, terlipressin, is classified as a vasopressin receptor agonist (i.e., it binds to and activates vasopressin receptors). In the labeled indication, terlipressin (TERLIVAZ) is indicated for improving renal function in adults with hepatorenal syndrome associated with rapid reduction in kidney function. A labeled warning for terlipressin notes risk of severe respiratory failure, including fatal cases.

Sources for this introduction: [1] [2] [3] [4]

This published profile is a reference in progress. Findings retain their source context; missing topics are marked below.

What is it?

A molecule, not a product name.

Identity

Terlipressin is described chemically as a peptide composed of 12 amino acids.

Sources[1]dailymedThese highlights do not include all the information needed to use TERLIVAZ®safely and effectively. See full prescribing information for TERLIVAZ.TERLIVAZ (terlipressin) for injection, for intravenous useInitial U.S. Approval: 2022Terlipressin is a 12-amino acid peptide with the chemical nameN-[N-(N-glycylglycyl)glycyl]-8-L-lysinevasopressin.[2]pubmedEvaluation of Terlipressin and In-Hospital Mortality in the Treatment of Hepatorenal Syndrome-Acute Kidney Injury (HRS-AKI).Terlipressin is a synthetic vasopressin analogue
Source records
2
Independent studies
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Terlipressin is a 12-amino acid peptide with the chemical nameN-[N-(N-glycylglycyl)glycyl]-8-L-lysinevasopressin.”

    These highlights do not include all the information needed to use TERLIVAZ®safely and effectively. See full prescribing information for TERLIVAZ.TERLIVAZ (terlipressin) for injection, for intravenous useInitial U.S. Approval: 2022 · 11 DESCRIPTION

    dailymed:3a35b86c-f451-4fac-8499-43019e4da354:d3cf759c2742:d3cf759c2742
  2. supports · Source-backed record
    “Terlipressin is a synthetic vasopressin analogue”

    Evaluation of Terlipressin and In-Hospital Mortality in the Treatment of Hepatorenal Syndrome-Acute Kidney Injury (HRS-AKI). · BACKGROUND

    pubmed:42500941:016633ebe7d5:016633ebe7d5

How does it work?

Target, response, and disposition.

Mechanism

The product’s active ingredient, terlipressin, is classified as a vasopressin receptor agonist (i.e., it binds to and activates vasopressin receptors).

Sources[1]dailymedThese highlights do not include all the information needed to use TERLIVAZ®safely and effectively. See full prescribing information for TERLIVAZ.TERLIVAZ (terlipressin) for injection, for intravenous useInitial U.S. Approval: 2022TERLIVAZ contains terlipressin, a vasopressin receptor agonist.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “TERLIVAZ contains terlipressin, a vasopressin receptor agonist.”

    These highlights do not include all the information needed to use TERLIVAZ®safely and effectively. See full prescribing information for TERLIVAZ.TERLIVAZ (terlipressin) for injection, for intravenous useInitial U.S. Approval: 2022 · 11 DESCRIPTION

    dailymed:3a35b86c-f451-4fac-8499-43019e4da354:d3cf759c2742:d3cf759c2742

What has been studied?

What the evidence says.

Study findings

In the labeled indication, terlipressin (TERLIVAZ) is indicated for improving renal function in adults with hepatorenal syndrome associated with rapid reduction in kidney function.

Sources[1]dailymedThese highlights do not include all the information needed to use TERLIVAZ®safely and effectively. See full prescribing information for TERLIVAZ.TERLIVAZ (terlipressin) for injection, for intravenous useInitial U.S. Approval: 2022TERLIVAZ is indicated to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “TERLIVAZ is indicated to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function.”

    These highlights do not include all the information needed to use TERLIVAZ®safely and effectively. See full prescribing information for TERLIVAZ.TERLIVAZ (terlipressin) for injection, for intravenous useInitial U.S. Approval: 2022 · 1 INDICATIONS AND USAGE

    dailymed:3a35b86c-f451-4fac-8499-43019e4da354:d3cf759c2742:d3cf759c2742

Risks and interactions

Risks, organized for scanning.

Contraindications

Per labeled contraindications, terlipressin should not be used in patients with hypoxia or worsening respiratory symptoms.

Sources[1]dailymedThese highlights do not include all the information needed to use TERLIVAZ®safely and effectively. See full prescribing information for TERLIVAZ.TERLIVAZ (terlipressin) for injection, for intravenous useInitial U.S. Approval: 2022TERLIVAZ is contraindicated in patients experiencing hypoxia or worsening respiratory symptoms.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “TERLIVAZ is contraindicated in patients experiencing hypoxia or worsening respiratory symptoms.”

    These highlights do not include all the information needed to use TERLIVAZ®safely and effectively. See full prescribing information for TERLIVAZ.TERLIVAZ (terlipressin) for injection, for intravenous useInitial U.S. Approval: 2022 · 4 CONTRAINDICATIONS

    dailymed:3a35b86c-f451-4fac-8499-43019e4da354:d3cf759c2742:d3cf759c2742

Safety findings

A labeled warning for terlipressin notes risk of severe respiratory failure, including fatal cases.

Sources[1]dailymedThese highlights do not include all the information needed to use TERLIVAZ®safely and effectively. See full prescribing information for TERLIVAZ.TERLIVAZ (terlipressin) for injection, for intravenous useInitial U.S. Approval: 2022TERLIVAZ may cause serious or fatal respiratory failure.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “TERLIVAZ may cause serious or fatal respiratory failure.”

    These highlights do not include all the information needed to use TERLIVAZ®safely and effectively. See full prescribing information for TERLIVAZ.TERLIVAZ (terlipressin) for injection, for intravenous useInitial U.S. Approval: 2022 · WARNING: SERIOUS OR FATAL RESPIRATORY FAILURE

    dailymed:3a35b86c-f451-4fac-8499-43019e4da354:d3cf759c2742:d3cf759c2742

Safety findings

The label indicates that pediatric safety and efficacy data are insufficient to establish use in pediatric patients.

Sources[1]dailymedThese highlights do not include all the information needed to use TERLIVAZ®safely and effectively. See full prescribing information for TERLIVAZ.TERLIVAZ (terlipressin) for injection, for intravenous useInitial U.S. Approval: 2022Safety and effectiveness of TERLIVAZ have not been established in pediatric patients.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Safety and effectiveness of TERLIVAZ have not been established in pediatric patients.”

    These highlights do not include all the information needed to use TERLIVAZ®safely and effectively. See full prescribing information for TERLIVAZ.TERLIVAZ (terlipressin) for injection, for intravenous useInitial U.S. Approval: 2022 · 8.4 Pediatric Use

    dailymed:3a35b86c-f451-4fac-8499-43019e4da354:d3cf759c2742:d3cf759c2742

Products and regulatory status

Same ingredient. Different records.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Administration context

The practical clinical context.

Administration

For preparation of terlipressin injection, each vial is reconstituted with 5 mL 0.9% sodium chloride, yielding a concentration of 0.85 mg per 5 mL.

Sources[1]dailymedThese highlights do not include all the information needed to use TERLIVAZ®safely and effectively. See full prescribing information for TERLIVAZ.TERLIVAZ (terlipressin) for injection, for intravenous useInitial U.S. Approval: 2022Reconstitute each vial with 5 mL of 0.9% Sodium Chloride Injection to prepare a 0.85 mg/5 mL solution.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Reconstitute each vial with 5 mL of 0.9% Sodium Chloride Injection to prepare a 0.85 mg/5 mL solution.”

    These highlights do not include all the information needed to use TERLIVAZ®safely and effectively. See full prescribing information for TERLIVAZ.TERLIVAZ (terlipressin) for injection, for intravenous useInitial U.S. Approval: 2022 · 2.3 Preparation and Administration

    dailymed:3a35b86c-f451-4fac-8499-43019e4da354:d3cf759c2742:d3cf759c2742

Dose records

Recommended initiation dosing for terlipressin (TERLIVAZ) is 0.85 mg q6h, administered as a slow IV bolus over 2 minutes for the first 3 days.

Sources[1]dailymedThese highlights do not include all the information needed to use TERLIVAZ®safely and effectively. See full prescribing information for TERLIVAZ.TERLIVAZ (terlipressin) for injection, for intravenous useInitial U.S. Approval: 2022The recommended starting dosage is TERLIVAZ 0.85 mg every 6 hours by slow intravenous bolus injection (over 2 minutes) on Days 1 through 3.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “The recommended starting dosage is TERLIVAZ 0.85 mg every 6 hours by slow intravenous bolus injection (over 2 minutes) on Days 1 through 3.”

    These highlights do not include all the information needed to use TERLIVAZ®safely and effectively. See full prescribing information for TERLIVAZ.TERLIVAZ (terlipressin) for injection, for intravenous useInitial U.S. Approval: 2022 · 2.2 Recommended Dosage

    dailymed:3a35b86c-f451-4fac-8499-43019e4da354:d3cf759c2742:d3cf759c2742

Research status + gaps

What still needs better answers?

  • No publishable claim yet for: interaction, regulatory
  • 14 compiled claim(s) withheld by automated assurance: assurance_score_below_0.58 (11), assurance_score_below_0.72 (2), current_regulatory_source_required (1), extraction_ambiguity (8), extraction_confidence_not_high (5), high_risk_requires_regulatory_or_two_independent_sources (3), no_direct_support (13)

These are the limits of this profile, not an exhaustive list of scientific uncertainties.

References + discovery

Open the records yourself.

  1. These highlights do not include all the information needed to use TERLIVAZ®safely and effectively. See full prescribing information for TERLIVAZ.TERLIVAZ (terlipressin) for injection, for intravenous useInitial U.S. Approval: 2022 ↗

    dailymed · published 2026-06-19 · retrieved 2026-09-04T22:25:11Z

  2. Evaluation of Terlipressin and In-Hospital Mortality in the Treatment of Hepatorenal Syndrome-Acute Kidney Injury (HRS-AKI). ↗

    pubmed · published 2026-07-25 · retrieved 2026-08-21T17:03:42Z

Publication history and provenance

Version 4 · Automated assessment · 2026-09-04T22:25:11Z

bae4f20dbf293565b1ff174bb71b45dcfe92a59bd5f130037ae8b112e41ce4cd